RT Journal Article
SR Electronic
T1 High vaccine effectiveness against severe Covid-19 in the elderly in Finland before and after the emergence of Omicron
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.11.22272140
DO 10.1101/2022.03.11.22272140
A1 Baum, Ulrike
A1 Poukka, Eero
A1 Leino, Tuija
A1 Kilpi, Terhi
A1 Nohynek, Hanna
A1 Palmu, Arto A.
YR 2022
UL http://medrxiv.org/content/early/2022/03/13/2022.03.11.22272140.abstract
AB Background The elderly are highly vulnerable to severe Covid-19. Waning immunity and emergence of Omicron have caused concerns about reduced effectiveness of Covid-19 vaccines. The objective was to estimate vaccine effectiveness (VE) against severe Covid-19 among the elderly.Methods This nationwide, register-based cohort study included all residents aged 70 years and over in Finland. The follow-up started on December 27, 2020, and ended on February 19, 2022. The study outcomes were Covid-19-related hospitalization and intensive care unit (ICU) admission timely associated with SARS-CoV-2 infection. VE was estimated as 1 minus the hazard ratio comparing the vaccinated and unvaccinated and taking into account time since vaccination. Omicron-specific VE was evaluated as the effectiveness observed since January 01, 2022.Results The cohort included 897932 individuals. Comirnaty (BioNTech/Pfizer) VE against Covid-19-related hospitalization was 93% (95% confidence interval [CI], 90%–95%) and 87% (84%–89%) 14–90 and 91–180 days after the second dose; VE increased to 96% (95%–97%) 14–60 days after the third dose. VE of other homologous and heterologous 3-dose series was similar. Protection against severe Covid-19 requiring ICU treatment was even better. Since January 01, 2022, Comirnaty VE was 91% (95% CI, 79%–96%) and 76% (56%–86%) 14–90 and 91–180 days after the second and 95% (94%–97%) 14–60 days after the third dose.Conclusions VE against severe Covid-19 is high among the elderly. It waned slightly after 2 doses, but a third restored the protection. VE against severe Covid-19 remained high even after the emergence of Omicron.Competing Interest StatementNo financial conflicts related to the current work. Finnish Institute for Health and Welfare (THL) conducts Public-Private Partnership with vaccine manufacturers and has received research funding from Sanofi Inc., Pfizer Inc., and GlaxoSmithKline Biologicals SA for non-COVID-19-related studies. AAP has been an investigator in these studies but has received no personal remuneration.Funding StatementNo external funding. This study was funded by the Finnish Institute for Health and Welfare (THL).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:A waiver of ethical approval was received from Professor Mika Salminen, Director of the Department for Health Security Finnish Institute for Health and Welfare (see supplement material).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesBy Finnish law, the authors are not permitted to share individual-level register data. The computing code is available upon request.